Company Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries.
Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins.
The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Country | United States |
| IPO Date | Nov 6, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 325 |
| CEO | Richard A. Paulson M.B.A. |
Contact Details
Address: 85 Wells Avenue Newton, Massachusetts United States | |
| Website | https://www.karyopharm.com |
Stock Details
| Ticker Symbol | KPTI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001503802 |
| CUSIP Number | 48576U106 |
| ISIN Number | US48576U1060 |
| Employer ID | 26-3931704 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard A. Paulson M.B.A. | President, Chief Executive Officer & Director |
| Brendan Twohig Strong | SVice President of Investor Relations & Corporate Communications |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive Vice President, Chief Medical Officer & Head of Research |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| James Accumanno J.D. | Chief Compliance Officer |
| Kristin Abate | Vice President, Chief Accounting Officer, Interim Principal Financial Officer & Assistant Treasurer |
| Michael J. Mano J.D. | Senior Vice President, General Counsel & Secretary |
| Sohanya Cheng M.B.A. | Executive Vice President, Chief Commercial Officer & Head of Business Development |
| Stuart Poulton | Executive Vice President & Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 05, 2024 | PRE 14A | Filing |
| Dec 05, 2024 | 4 | Filing |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 3 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 06, 2024 | 4 | Filing |
| Nov 05, 2024 | S-8 | Filing |